Ebert Katharina, Maurice Elena, Lukačin Richard, Fleischhaker Christian, Schulz Eberhard, Ebert Dieter, Clement Hans-Willi
Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Centre for Mental Health, University Hospital of Freiburg, Freiburg.
Chromsystems Instruments & Chemicals GmbH, Gräfelfing. Dr. Lukacin is now with RECIPE Chemicals and Instruments GmbH, Munich, Germany.
Ther Drug Monit. 2018 Jun;40(3):351-355. doi: 10.1097/FTD.0000000000000508.
Therapeutic drug monitoring has become increasingly important in psychiatric therapy. However, it is not yet implemented as a daily routine in clinical settings. To evaluate new, noninvasive procedures, we compared blood and saliva venlafaxine, quetiapine, and citalopram concentrations in samples collected from psychiatric patients.
We collected blood and saliva samples from 75 psychiatric patients (39 venlafaxine, 19 quetiapine, and 17 citalopram). Saliva sampling was achieved by the use of cotton pads. Venlafaxine (and its metabolite O-desmethylvenlafaxine) and quetiapine were analyzed by LC-MS/MS, whereas citalopram was analyzed by HPLC.
We observed significant correlations between concentrations of venlafaxine (ratio saliva/serum ± SD: 18.3 ± 9.5, P < 0.01, r = 0.895) and its metabolite O-desmethylvenlafaxine (ratio saliva/serum ± SD: 4.1 ± 3.2, P < 0.05, r = 0.344), quetiapine (ratio saliva/serum ± SD: 0.2 ± 0.2, P < 0.01, r = 0.935), and citalopram (ratio saliva/serum ± SD: 2.6 ± 1.2, P < 0.05, r = 0.54) in serum and in saliva. Furthermore, measured concentrations of venlafaxine (and its metabolite O-desmethylvenlafaxine) and citalopram were higher in saliva than in serum, whereas measured concentrations of quetiapine were higher in serum than in saliva.
Using cotton pad saliva sampling, venlafaxine and quetiapine demonstrate high correlations between saliva and serum concentrations, whereas for O-desmethylvenlafaxine and citalopram, other methods of sampling might be preferable. Saliva therapeutic drug monitoring of psychoactive drugs might become a useful approach to achieving individual treatment regimens.
治疗药物监测在精神科治疗中变得越来越重要。然而,在临床环境中它尚未成为日常常规操作。为了评估新的非侵入性程序,我们比较了从精神科患者采集的样本中血液和唾液中的文拉法辛、喹硫平和西酞普兰浓度。
我们从75名精神科患者(39名服用文拉法辛、19名服用喹硫平、17名服用西酞普兰)采集了血液和唾液样本。唾液采样通过使用棉垫完成。文拉法辛(及其代谢物O - 去甲基文拉法辛)和喹硫平通过液相色谱 - 串联质谱法分析,而西酞普兰通过高效液相色谱法分析。
我们观察到文拉法辛(唾液/血清比值±标准差:18.3±9.5,P < 0.01,r = 0.895)及其代谢物O - 去甲基文拉法辛(唾液/血清比值±标准差:4.1±3.2,P < 0.05,r = 0.344)、喹硫平(唾液/血清比值±标准差:0.2±0.2,P < 0.01,r = 0.935)和西酞普兰(唾液/血清比值±标准差:2.6±1.2,P < 0.05,r = 0.54)在血清和唾液中的浓度之间存在显著相关性。此外,测得的文拉法辛(及其代谢物O - 去甲基文拉法辛)和西酞普兰在唾液中的浓度高于血清,而测得的喹硫平在血清中的浓度高于唾液。
使用棉垫唾液采样,文拉法辛和喹硫平在唾液和血清浓度之间显示出高度相关性,而对于O -去甲基文拉法辛和西酞普兰,可能更适合采用其他采样方法。对精神活性药物进行唾液治疗药物监测可能成为实现个体化治疗方案的一种有用方法。